-
The FDA has approved a new antifungal agent for the prevention of Aspergillus and Candida infections in at-risk individuals. Posaconazole is an oral triazole, broad spectrum, antifungal chemically similar to itraconazole.
-
In the United States, COPD is the 4th leading cause of death. Widespread public education about smoking toxicity has not decreased COPD mortality, and since 2000 the number of women who die from COPD has eclipsed men.
-
Moderate alcohol intake was associated with longer survival and better quality of life scores for Australian women age 70-75 years old, while non-drinkers had greater risk of death and poorer health-related quality.
-
Cluster headache may be accompanied by a variety of neurological manifestations, and responds well to triptans and oxygen therapy.
-
-
-
A total of 2084 men from two Framingham Heart Study cohorts had endogenous levels of total serum estrogen, testosterone and dehydroepiandrosterone sulfate (DHEA-S) measured.
-
A retrospective review of patient records representing preventive healthcare visits of women aged 50-69 revealed that gynecologists are more likely than family physicians or internists to follow breast cancer screening guidelines.
-
Treatment of Parkinson's disease with dopamine agonist medications may precipitate impulse-control disorders such as compulsive gambling, buying, and hypersexuality.
-
The FDA has approved the first product for the treatment of Hunter syndrome. Idursulfase is a purified form of iduronate-2-sulfase, a 525-amino acid glycoprotein, produced by recombinant DNA technology.
